{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:56:25Z","timestamp":1791924985693,"version":"4.3.4"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The tumor microenvironment is more than a backdrop for malignant cells: stromal fibroblasts, extracellular matrix, abnormal vasculature, hypoxia, and immunosuppressive myeloid and lymphoid populations act together to limit both drug delivery and treatment response. Here, we examine nanomedicine along three linked axes: stromal remodeling, hypoxia control, and photodynamic immune activation. CAF-directed and matrix-responsive carriers can improve perfusion and intratumoral transport; however, because fibroblasts are heterogeneous, subtype-selective reprogramming is safer than wholesale depletion, which can worsen outcomes. Oxygen-generating, hypoxia-activated, and oxygen-conserving Type I photochemical systems address both pre-existing hypoxia and the additional oxygen depletion that PDT itself causes. We consider immune-active nanocarriers, such as STING agonists and mRNA vaccines, because stromal access and hypoxic stress shape their distribution, while PDT-induced immunogenic cell death supplies the antigenic and inflammatory signals on which these platforms are built. Pancreatic ductal adenocarcinoma remains the archetype of desmoplasia, yet we deliberately contrast it with glioblastoma, breast, ovarian, and other solid tumors, whose microenvironments differ in important ways. Translation is still held back by variable and often low tumor delivery, protein-corona formation, off-target clearance, manufacturing complexity, and inconsistent patient selection. The more realistic path forward is not ever-greater carrier complexity, but biomarker-guided, mechanism-matched platforms with measurable microenvironmental endpoints and a clear route to scalable production.<\/jats:p>","DOI":"10.3389\/fonc.2026.1914117","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:08:04Z","timestamp":1787839684000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanomedicine strategies for remodeling the solid tumor microenvironment: stromal targeting, hypoxia modulation, and photodynamic immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Mohd Ahmar","family":"Rauf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Heme\/Oncology Unit, University of Michigan","place":["Ann Arbor, MI, United States"]},{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy","family":"Luong","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medical and Translational Biology, Umea University","place":["Umea, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University","place":["Detroit, MI, United States"]},{"name":"Molecular Imaging Program, Karmanos Cancer Institute, Wayne State School of Medicine","place":["Detroit, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and solid tumor microenvironment","volume":"99","author":"Tredan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.3653","article-title":"Normalizing the tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318415110","article-title":"Combining these two strategies can improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1021\/cr5004198","article-title":"Nanoparticles in photodynamic therapy","volume":"115","author":"Lucky","year":"2015","journal-title":"Chem Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201601902","article-title":"Intelligent albumin-MnO2 nanoparticles as pH-\/H2O2-responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy","volume":"28","author":"Chen","year":"2016","journal-title":"Adv Mater"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer-associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1894","article-title":"Photodynamic therapy and anti-tumour immunity","volume":"6","author":"Castano","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2021.10.004","article-title":"Revisiting the HIF switch in the tumor and its immune microenvironment","volume":"8","author":"Cowman","year":"2022","journal-title":"Trends Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/cr900300p","article-title":"Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization","volume":"110","author":"Celli","year":"2010","journal-title":"Chem Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201900132","article-title":"Photosensitizers for photodynamic therapy","volume":"8","author":"Lan","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/jca.126813","article-title":"A comprehensive review of nanotechnological innovations in cancer: From molecular pathways to clinical applications","volume":"17","author":"Nawaz","year":"2026","journal-title":"J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: Back to the basics","volume":"37","author":"Pure","year":"2018","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3041","article-title":"Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells","volume":"75","author":"Lo","year":"2015","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat Nanotechnol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.09.013","article-title":"Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles","volume":"172","author":"Ernsting","year":"2013","journal-title":"J Control Release"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.3c00266","article-title":"Matrix metalloproteinase-responsive drug delivery systems","volume":"34","author":"Zhang","year":"2023","journal-title":"Bioconjug Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","article-title":"The effect of nanoparticle size, shape, and surface chemistry on biological systems","volume":"14","author":"Albanese","year":"2012","journal-title":"Annu Rev BioMed Eng"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Delivery Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","article-title":"Challenges and strategies in anti-cancer nanomedicine development: An industry perspective","volume":"108","author":"Hare","year":"2017","journal-title":"Adv Drug Delivery Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-245","article-title":"FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","article-title":"Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology","volume":"9","author":"Semenza","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201901513","article-title":"A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy","volume":"31","author":"Yang","year":"2019","journal-title":"Adv Mater"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202307288","article-title":"Activatable Type I photosensitizer with quenched photosensitization pre and post photodynamic therapy","volume":"62","author":"Tian","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c05617","article-title":"Perfluorocarbon@porphyrin nanoparticles for tumor hypoxia relief to enhance photodynamic therapy against liver metastasis of colon cancer","volume":"14","author":"Liang","year":"2020","journal-title":"ACS Nano"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172","article-title":"Immune checkpoint therapy \u2013 current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg0539","article-title":"PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for accelerated differentiation into effectors","volume":"8","author":"Gill","year":"2023","journal-title":"Sci Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: From molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp Mol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: Mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: Results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2235","article-title":"Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: An open-label, multicenter, phase Ib study","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.9b01235","article-title":"M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKK\u03b2 siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects","volume":"6","author":"Xiao","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"32","DOI":"10.20892\/j.issn.2095-3941.2019.0372","article-title":"Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment","volume":"17","author":"Zhang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12499","article-title":"Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"7","author":"He","year":"2016","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41467-024-55529-8","article-title":"Hypoxia-tolerant polymeric photosensitizer prodrug for cancer photo-immunotherapy","volume":"16","author":"Yu","year":"2025","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cGAS\u2013STING pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41598-019-38554-2","article-title":"An implantable ultrasonically-powered micro-light-source for photodynamic therapy","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942)","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial","volume":"42","author":"Weber","year":"2024","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.7150\/thno.35343","article-title":"Enhanced cancer therapy through synergetic photodynamic\/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor","volume":"9","author":"Huang","year":"2019","journal-title":"Theranostics"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c03416","article-title":"Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"15","author":"Choi","year":"2021","journal-title":"ACS Nano"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn2941","article-title":"Copackaging photosensitizer and PD-L1 siRNA in a nucleic acid nanogel for synergistic cancer photoimmunotherapy","volume":"8","author":"Guo","year":"2022","journal-title":"Sci Adv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.2c12774","article-title":"Photocontrolled spatiotemporal delivery of DNA immunomodulators for enhancing membrane-targeted tumor photodynamic immunotherapy","volume":"14","author":"Wang","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"B69","doi-asserted-by":"publisher","first-page":"7672","DOI":"10.1038\/s41467-025-63081-2","article-title":"Bioengineered hybrid dual-targeting nanoparticles reprogram the tumour microenvironment for deep glioblastoma photodynamic therapy","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat Mater"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116627","article-title":"Engineering the protein corona: strategies, effects, and future directions in nanoparticle therapeutics","volume":"175","author":"Zhao","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4007","article-title":"MAESTRO: a randomized, double-blind phase III study of evofosfamide in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil \u2013 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"AAPS J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1038\/s41467-018-04703-w","article-title":"Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy","volume":"9","author":"Ni","year":"2018","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12283","article-title":"Plant-derived extracellular vesicles: recent advancements and current challenges for biomedical applications","volume":"11","author":"Lian","year":"2022","journal-title":"J Extracell Vesicles"},{"key":"B82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s13346-024-01621-x","article-title":"Plant-derived exosome-like nanoparticles for microRNA delivery in cancer treatment","volume":"15","author":"Yi","year":"2025","journal-title":"Drug Delivery Transl Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503138","article-title":"Machine learning-enhanced nanoparticle design for precision cancer drug delivery","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B85","volume-title":"Drug Products, Including Biological Products, That Contain Nanomaterials: Guidance for Industry","year":"2022"},{"key":"B86","volume-title":"ISO\/TS 23302:2021 Nanotechnologies - Requirements and Recommendations for the Identification of Measurands That Characterize Nano-Objects and Materials That Contain Them","year":"2021"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:08:05Z","timestamp":1787839685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":87,"alternative-id":["10.3389\/fonc.2026.1914117"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1914117","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1914117"}}